Repligen Corporation (RGEN)

NASDAQ: RGEN · IEX Real-Time Price · USD
168.36
-1.21 (-0.71%)
Mar 31, 2023, 4:00 PM EDT - Market closed
-0.71%
Market Cap 9.35B
Revenue (ttm) 801.54M
Net Income (ttm) 185.96M
Shares Out 55.56M
EPS (ttm) 3.24
PE Ratio 51.96
Forward PE 56.50
Dividend n/a
Ex-Dividend Date n/a
Volume 543,926
Open 171.25
Previous Close 169.57
Day's Range 167.73 - 173.84
52-Week Range 137.21 - 262.26
Beta 1.09
Analysts Buy
Price Target 207.26 (+23.11%)
Earnings Date Apr 26, 2023

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput... [Read more]

Sector Healthcare
Founded 1981
Employees 1,852
Stock Exchange NASDAQ
Ticker Symbol RGEN
Full Company Profile

Financial Performance

In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $207.26, which is an increase of 23.11% from the latest price.

Price Target
$207.26
(23.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

1 week ago - Zacks Investment Research

Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum

WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt...

2 weeks ago - GlobeNewsWire

Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates

Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.

1 month ago - Zacks Investment Research

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 17.24% and 0.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Repligen Reports Fourth Quarter and Full Year 2022 Financial Results

WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f...

1 month ago - GlobeNewsWire

Repligen Appoints Martin D. Madaus to Board of Directors

WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus.

1 month ago - GlobeNewsWire

Repligen to Report Fourth Quarter and Full Year 2022 Financial Results

Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST

1 month ago - GlobeNewsWire

HZNP vs. RGEN: Which Stock Is the Better Value Option?

HZNP vs. RGEN: Which Stock Is the Better Value Option?

Other symbols: HZNP
2 months ago - Zacks Investment Research

Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at th...

3 months ago - GlobeNewsWire

Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

BIIB or RGEN: Which Is the Better Value Stock Right Now?

BIIB vs. RGEN: Which Stock Is the Better Value Option?

Other symbols: BIIB
4 months ago - Zacks Investment Research

Is Repligen a Value Trap or a Value Opportunity?

The past 14 months have disappointed many shareholders of Repligen Corp. ( RGEN , Financial). Its price fell from $324.21 on Sept.

4 months ago - GuruFocus

Frank Sands Is Loading Up on This Underestimated Biopharma Stock

Sands Capital Management recently disclosed its 13F portfolio updates for the third quarter of 2022, which ended on Sept. 30.

5 months ago - GuruFocus

Repligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at tw...

5 months ago - GlobeNewsWire

BIIB vs. RGEN: Which Stock Is the Better Value Option?

BIIB vs. RGEN: Which Stock Is the Better Value Option?

Other symbols: BIIB
5 months ago - Zacks Investment Research

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

5 months ago - Zacks Investment Research

Repligen (RGEN) Q3 Earnings and Revenues Top Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 13.24% and 4.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its t...

5 months ago - GlobeNewsWire

Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands

WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (“Purolite”), ...

5 months ago - GlobeNewsWire

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?

Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

5 months ago - Zacks Investment Research

LGND vs. RGEN: Which Stock Is the Better Value Option?

LGND vs. RGEN: Which Stock Is the Better Value Option?

Other symbols: LGND
5 months ago - Zacks Investment Research

Repligen (RGEN) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

5 months ago - Zacks Investment Research

Repligen to Report Third Quarter 2022 Financial Results

Webcast and Conference Call to Be Held Tuesday, November 1, 2022 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, November 1, 2022 at 8:30 a.m. EDT

6 months ago - GlobeNewsWire

4 under-the-radar stock picks from a five-star fund manager who sees rewards that are worth the risks

It can be tempting to chase performance during any given year, but unfortunately it's a tried-and-true way to lower your investment returns in the long run.

Other symbols: FIVEPYCRSWAV
6 months ago - Market Watch

REGN vs. RGEN: Which Stock Is the Better Value Option?

REGN vs. RGEN: Which Stock Is the Better Value Option?

Other symbols: REGN
6 months ago - Zacks Investment Research